If approved, Apnimed’s sleep apnea pill AD109 would be the first pharmacologic treatment to target the underlying cause of airway collapse in adults.
RT’s Three Key Takeaways:
- Regulatory Milestone: The FDA has accepted the New Drug Application for AD109 and assigned a target action date of Feb 28, 2027.
- Novel Treatment Mechanism: AD109 is designed as a once-daily oral pill that targets the neuromuscular root cause of obstructive sleep apnea rather than relying on devices or surgery.
- Phase 3 Success: Clinical trials demonstrated that the medication significantly reduced the apnea-hypopnea index and improved oxygenation levels in patients with mild to severe sleep apnea.
The FDA has accepted for review a New Drug Application (NDA) for AD109, an investigational oral pill for the treatment of adults with obstructive sleep apnea (OSA), according to Apnimed. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of Feb 28, 2027.
AD109 (aroxybutynin 2.3 mg/atomoxetine 75 mg) is designed to address the neuromuscular root cause of upper airway collapse. If approved, the company stated it has the potential to become the first oral pharmacologic therapy for the millions of people living with OSA.
“The FDA acceptance of our NDA is an important milestone for Apnimed as we advance toward our goal of expanding treatment options for people with OSA who continue to need more accessible solutions,” said Kevin Lind, chief executive officer of Apnimed, in a news release. “The NDA is supported by a clinical data package that reflects years of scientific innovation focused on a major unmet need.”
Clinical Trial Results
The NDA submission is supported by data from the company’s Phase 3 clinical program, which included the SynAIRgy and LunAIRo randomized, double-blind, placebo-controlled trials. These studies evaluated AD109 in adults with mild, moderate, and severe OSA.
Across both trials, AD109 demonstrated statistically significant reductions in the apnea-hypopnea index (AHI). The medication also showed improvements in oxygenation metrics, including hypoxic burden and the oxygen desaturation index, according to the news release.
The drug was generally well-tolerated during the Phase 3 program. The most common adverse events reported were dry mouth, insomnia, and nausea, which the company noted were consistent with earlier clinical trials.
A New Treatment Paradigm
AD109 is a combination of aroxybutynin, a novel antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor. The once-daily pill is taken at bedtime and is intended to lower the complexity of intervention for patients who currently rely on more invasive or cumbersome options.
OSA is a chronic sleep-related breathing disease characterized by repeated upper airway collapse during sleep, which leads to intermittent oxygen deprivation. The condition is caused by neuromuscular dysfunction and predisposing anatomic abnormalities. An estimated 80 million people in the US and one billion people worldwide suffer from the condition.
Failure to effectively treat OSA increases the risk of serious long-term healthcare consequences, including cardiovascular, neurocognitive, and cardiometabolic damage. While the disease affects individuals across all ethnicities and weight classes, many diagnosed patients currently remain untreated due to the limitations of existing device-based therapies or surgeries.
